Anavex Life Sciences Corp (AVXL)

[dia76ca]

Those who subscribe to seeking alpha will find a largely positive article just came out.
"Anavex Life Sciences: The Little Company That Did"
Dec. 06, 2022 12:51 PM ET
Anavex Life Sciences Corp. (AVXL)
Lane Simonian

Summary
Anavex's 2-73/blarcamesine produced significant reductions in cognitive decline in early Alzheimer's disease as measured by ADAS-Cog and CDR-SB scores.
Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically significant.
In an earlier phase 2a trial, most (4 out of 6) high concentration patients improved, whereas no medium concentration patients improved.
The high dose group patients in the phase 2b/3 clinical trial are likely to do considerably better than the pooled 30mg and 50mg group.
It is very difficult to gauge how the FDA will decide on blarcamesine; such a decision will be critical to Anavex's stock value.